[{"company":"AbCellera","sponsor":"Government of Canada","pharmaFlowCategory":"D","amount":"$175.6 million","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Gets Funding for Drug Discovery Technology That Identifies Antibodies for Potential Use in drugs to treat and prevent COVID-19.","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCellera"},{"company":"AbCellera","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Announces Multi-Year Antibody Discovery Collaboration with Lilly","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCellera"},{"company":"Vaxxas","sponsor":"Merck & Co. Inc.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Vaxxas"},{"company":"Ardigen","sponsor":"CVC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ardigen, CVC Collaborate to Develop SARS-CoV-2 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Ardigen"},{"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"$1.3 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Relation Therapeutics"},{"company":"Door Pharmaceuticals","sponsor":"Assembly Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Assembly Biosciences and Door Pharmaceuticals Ink Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Door Pharmaceuticals"},{"company":"PeptiDream","sponsor":"Fujitsu","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Japan's Fujitsu, Mizuho, PeptiDream to Establish Joint Venture to Develop COVID-19 Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Peptide","graph2":"PeptiDream"},{"company":"TScan Therapeutics","sponsor":"Poseida Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Poseida Therapeutics and TScan Therapeutics Collaborate to Explore Developing Allogeneic T Cell Receptor Therapies for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"TScan Therapeutics"},{"company":"Cristal Therapeutics","sponsor":"Intravacc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Cristal Therapeutics"},{"company":"TenNor Therapeutics","sponsor":"Janssen Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"TenNor Therapeutics"},{"company":"Delonix Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Delonix Bioworks Closes $14 Million Series Seed Financing to Accelerate the Development of its Innovative Synthetic Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Delonix Bioworks"},{"company":"AbCellera","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"AbCellera"},{"company":"Cincinnati Children's Hospital Medical Center","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Blue Water Vaccines Inks Exclusive, Global License Agreement of Novel Vaccine Platform from Cincinnati Children's Hospital Medical Center","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Cincinnati Children's Hospital Medical Center"},{"company":"Locus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Locus Biosciences Secures Financing of up to $25 Million from Hercules Capital","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Locus Biosciences"},{"company":"Cyclica","sponsor":"Structural Genomics Consortium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discovery","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Cyclica"},{"company":"Baidu Research","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Baidu Enters Into License Agreement With Sanofi to Enable Next-Generation mRNA Therapeutics and Vaccines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Baidu Research"},{"company":"ArrePath","sponsor":"Venture Fund","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"ArrePath Announces $20 Million Seed Financing to Advance its Machine Learning-based Platform for Discovery of Novel Anti-infectives Addressing Antimicrobial Resistance","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"ArrePath"},{"company":"GreenLight Biosciences","sponsor":"Serum Institute of India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serum Institute of India and GreenLight Biosciences Multitarget Licensing Agreement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"GreenLight Biosciences"},{"company":"Storm Therapeutics","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Storm Therapeutics"},{"company":"PostEra","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$68.0 million","upfrontCash":"Undisclosed","newsHeadline":"PostEra Spearheads AI-Driven Drug Discovery Collaboration to Develop Antiviral Therapeutics with Initial $68M in NIH Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PostEra"},{"company":"Quantitative Biosciences Institute","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$67.5 million","upfrontCash":"Undisclosed","newsHeadline":"UCSF QBI and QCRG Awarded Initial $67.5 Million from NIAID\/NIH to Develop Novel Therapies Against Viruses with Pandemic Potential","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Quantitative Biosciences Institute"},{"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Soligenix"}]
Details:
The candidate ThermoVax, filovirus vaccines have been previously shown to protect non-human primates (NHPs) from subsequent infection, and represent the only recombinant subunit vaccines that have demonstrated efficacy against Zaire ebolavirus and other filoviruses in NHPs.
Lead Product(s):
Filovirus Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: ThermoVax
Highest Development Status: Discovery Platform
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 23, 2022
Details:
ASAP will use PostEra's end-to-end AI-first approach to accelerate the discovery process, generating molecules with optimised properties, designing rapid synthesis, and optimally prioritising experiments.
Lead Product(s):
Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $68.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
May 18, 2022
Quantitative Biosciences Institute
Details:
The award covers a three-year period and establishes first Antiviral Drug Discovery Centers for Pathogens of Pandemic Concern, which are multidisciplinary academic-industry research centers to develop antivirals for COVID-19 and other viruses with pandemic potential.
Lead Product(s):
Antiviral Therapeutic
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
National Institute of Allergy and Infectious Diseases
Deal Size: $67.5 million
Upfront Cash: Undisclosed
Deal Type: Funding
May 18, 2022
Details:
The Innovate UK grant will allow STORM to develop a drug acting on a key coronavirus protein that is not targeted by current treatments. Generation of such a drug will provide a valuable option for treating Covid-19 and other coronavirus diseases.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Innovate Biopharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Funding
May 03, 2022
Details:
Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.
Lead Product(s):
mRNA-based Therapy
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Serum Institute of India
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
March 14, 2022
Details:
The funding will enable the advancement of initial leads and expansion of discovery efforts, as well as the enhancement of imaging platform and the application of machine learning in the discovery of new drugs to address critical global health challenges.
Lead Product(s):
Anti-infective Therapeutic
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Undisclosed
Partner/Sponsor/Collaborator:
Venture Fund
Deal Size: $20.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
March 03, 2022
Details:
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond Covid-19.
Lead Product(s):
mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
November 22, 2021
Details:
As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learning platform to assess commercially available libraries for potential binders.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Structural Genomics Consortium
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
November 11, 2021
Details:
Locus is developing two biotherapeutics to address unmet medical needs: precision products to fight deadly infections, including those caused by multi-drug resistant bacteria; and engineered bacteriophage therapies that utilize bacteria resident in the body.
Lead Product(s):
Engineered Bacteriophage
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Hercules Capital
Deal Size: $25.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
October 19, 2021
Cincinnati Children's Hospital Medical Center
Details:
The platform leverages norovirus capsid proteins to present foreign antigens for immune enhancement. The Cincinnati Children's researchers from the Division of Infectious Diseases bioengineered nanoparticles and polymers that are easily produced, stable and immunogenic.
Lead Product(s):
Undisclosed
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: Discovery Platform
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Blue Water Vaccines
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
July 13, 2021
Market Place
Company
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
